Detalhe da pesquisa
1.
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
N Engl J Med
; 388(9): 813-823, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36856617
2.
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
Cancer
; 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38376917
3.
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
BMC Cancer
; 23(1): 265, 2023 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949413
4.
The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity.
J Natl Compr Canc Netw
; 20(4): 417-425, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390763
5.
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
Endocr Pract
; 28(7): 719-731, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477029
6.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(11): 1465-1477, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961119
7.
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
Lancet Oncol
; 20(7): e378-e389, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31267972
8.
Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Semin Liver Dis
; 38(4): 366-378, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30357774
9.
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Gastroenterology
; 160(3): 932-934.e3, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33096100
10.
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
Mod Pathol
; 28(4): 480-6, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25376477
11.
Exploring Adolescent and Young Adult Cancer Survivors' Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured Interviews.
J Adolesc Young Adult Oncol
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634665
12.
Ipilimumab and its toxicities: a multidisciplinary approach.
Oncologist
; 18(6): 733-43, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23774827
13.
Systemic therapy for inoperable and metastatic basal cell cancer.
Curr Treat Options Oncol
; 14(2): 237-48, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23558911
14.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Lancet Oncol
; 13(8): 773-81, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22805291
15.
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Lancet Oncol
; 13(8): 782-9, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22805292
16.
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma.
Am Soc Clin Oncol Educ Book
; 43: e390594, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229626
17.
Metastatic melanoma of the heart: Retrospective cohort study and systematic review of prevalence, clinical characteristics, and outcomes.
Cancer Med
; 12(3): 2356-2367, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35894689
18.
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.
Cancer Cell
; 41(2): 304-322.e7, 2023 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36638784
19.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Clin Cancer Res
; 29(17): 3352-3361, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058595
20.
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
JAMA Oncol
; 9(1): 128-134, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36326731